Safety of nifedipine in subjects with bronchial asthma and COPD

N. Nair, R. G. Townley, Againdra K. Bewtra, C. K. Nair

Research output: Contribution to journalArticle

15 Scopus citations


This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects. All subjects received nifedipine, 20 mg, sublingually. Spirometry was done pre-drug administration and every 20 minutes after for two hours. Parameters measured were forced vital capacity (FVC), forced expiratory volume in one second (FEV 1), and forced expiratory flow at 25 percent to 75 percent of total volume (FEF25-75%). Subjects with asthma and COPD were also given nifedipine 20 mg three times daily, orally for two weeks, and tested biweekly during this period. All bronchodilators, beta-blockers, and long acting nitrates were withheld for five half-lives of the drug prior to test day. There was no adverse effect on the pulmonary function. We found a statistically significant improvement (p1 after nifedipine. There was no tachyphlaxis at the end of two weeks. Nifedipine is safe in patients with asthma and/or chronic bronchitis.

Original languageEnglish
Pages (from-to)515-518
Number of pages4
Issue number4
Publication statusPublished - 1984


All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Nair, N., Townley, R. G., Bewtra, A. K., & Nair, C. K. (1984). Safety of nifedipine in subjects with bronchial asthma and COPD. Chest, 86(4), 515-518.